11月20日，精优药业(00858)盘中上涨39.58%，截至09:49，报0.067元/股，成交100.07万元。
精优药业控股有限公司是一家主要向中国市场推广、销售医药产品、研发基因相关技术并开发口服胰岛素产品（通过联营公司）的投资控股公司。公司在香港联合交易所有限公司主板上市，其股份在百慕达注册。
截至2023年年报，精优药业营业总收入5357.53万元、净利润-1.48亿元。
11月19日，预计2024年中报溢利约1亿港元至1.05亿港元。
11月29日，精优药业将披露2024财年中报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.